Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

XELJANZ / XELJANZ XR Drug Interactions (tofacitinib)

7 DRUG INTERACTIONS

Table 6 includes drugs with clinically important drug interactions when administered concomitantly with XELJANZ/XELJANZ XR/XELJANZ Oral Solution and instructions for preventing or managing them.

Table 6: Clinically Relevant Interactions Affecting XELJANZ/XELJANZ XR/XELJANZ Oral Solution When Coadministered with Other Drugs
Strong CP3A4 Inhibitors (e.g., ketoconazole)
Clinical ImpactIncreased exposure to tofacitinib
InterventionDosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended
[see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)]
Moderate CYP3A4 Inhibitors Coadministered with Strong CYP2C19 Inhibitors (e.g., fluconazole)
Clinical ImpactIncreased exposure to tofacitinib
InterventionDosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended
[see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)]
Strong CYP3A4 Inducers (e.g., rifampin)
Clinical ImpactDecreased exposure to tofacitinib and may result in loss of or reduced clinical response
InterventionCoadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended
[see Clinical Pharmacology, Figure 3 (12.3)]
Immunosuppressive Drugs (e.g., azathioprine, tacrolimus, cyclosporine)
Clinical ImpactRisk of added immunosuppression; coadministration with biologic DMARDs or potent immunosuppressants has not been studied in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, UC, or pcJIA.
InterventionCoadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended
[see Indications and Usage (1), Clinical Pharmacology, Figure 3 (12.3)]
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event